57-57
Bengtsson A, Sturfelt G, Rönnblom L, van Vollenhoven R, Wallén Öhman M, Tuvesson H, Lando P, Edman K, Liberg D, Källberg E, Olsson A, Leanderson T. A Phase I, Dose Escalation Study to Evaluate the Tolerability of ABR-215757 in patients with Systemic Lupus Erythematosus (SLE). EULAR (The European League Against Rheumatism) Conference held in Copenhagen June 10, 2009.
Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A, Roth J, Ivars F, Leanderson T. Identification of Human S100A9 as a Novel target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides. PLoS Biology April 2009, Vol 7, Issue 4:800-812. http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1000097
Liberg D, Källberg E, Olsson A, Bengtsson A, Rönnblom L, Leanderson T. Effect on Interferon-inducible gene expression signature by ABR-215757, a new drug in development for SLE). Poster abstract presented at ACR meeting, October, 2008.
Runström A, Cort N and Axelsson B. Steroid Sparing Effect of Paquinimod (ABR-215757) in Disease Development of Experimental Lupus in MRLlpr/lpr Mice. Poster abstract presented at 8th World Congress of Inflammation, June 2007.
Carlsten H et al. (2004) The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus. Int Immunopharmacol 4:1515-23.
Runström, Törngren, Lando, Bokarewa, Jonsson, Carlsten and Tarkowski. The New Orally Active Immunoregulator ABR-215757 Effectively Inhibits Development of Systemic Lupus Erythematosus in MRL lpr/lpr Mice. Poster presented at American College of Rheumatology (ACR), October, 2003.